Table 1.
Distribution of samples between the discovery and validation sets
| Disease | Discovery set (n = 706) |
Validation set (n = 474) |
||||||
|---|---|---|---|---|---|---|---|---|
| Sample number | Gender (% male) | Age (years) | eGFR (mL/min/1.73 m2) | Sample number | Gender (% male) | Age (years) | eGFR (mL/min/1.73 m2) | |
| FSGS | 79 | 62 | 41.3 ± 21.8 | 45.1 ± 26.7 | 31 | 55 | 29.1 ± 23.2 | 46.9 ± 32.7 |
| DN&N | 288 | 66 | 65.4 ± 13.8 | 40.0 ± 22.9 | 288 | 57 | 64.7 ± 10.7 | 55.6 ± 22.8 |
| IgAN | 122 | 65 | 42.6 ± 16.0 | 50.8 ± 29.8 | 57 | 63 | 37.0 ± 14.2 | 94.7 ± 30.0 |
| MCD | 25 | 72 | 35.1 ± 15.2 | 85.8 ± 35.9 | 10 | 40 | 45.7 ± 23.2 | 103.4 ± 53.9 |
| MN | 55 | 74 | 52.0 ± 15.2 | 68.5 ± 32.4 | 22 | 67 | 50.9 ± 16.4 | 89.6 ± 22.3 |
| LN | 63 | 17 | 39.8 ± 12.6 | 57.1 ± 23.5 | 29 | 13 | 35.6 ± 13.4 | 99.3 ± 17.6 |
| Vasculitis-induced kidney disease | 74 | 58 | 64.5 ± 10.3 | 41.3 ± 22.4 | 37 | 44 | 58.8 ± 14.6 | 70.2 ± 13.7 |
The ‘±’ values indicate standard deviation.